Anthera Pharmaceuticals (OTCMKTS:ANTH) Stock Price Passes Above 200-Day Moving Average – Here’s What Happened
by Kim Johansen · The Markets DailyAnthera Pharmaceuticals, Inc. (OTCMKTS:ANTH – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $0.0001. Anthera Pharmaceuticals shares last traded at $0.00, with a volume of 0 shares changing hands.
Anthera Pharmaceuticals Trading Down 100.0%
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, trading on the OTC Markets under the symbol ANTH, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for patients suffering from serious and rare inflammatory and autoimmune diseases. The company’s research and development efforts center on both biologic and small-molecule approaches designed to modulate key pathways in immune system dysfunction. Anthera’s strategy includes advancing lead candidates through late-stage clinical trials while exploring additional indications for its pipeline assets.
The company’s most advanced asset, blisibimod, is a selective antagonist of B-cell activating factor (BAFF) that has been evaluated in clinical studies for systemic lupus erythematosus (SLE) and primary immune thrombocytopenia (ITP).
Further Reading
- Five stocks we like better than Anthera Pharmaceuticals
- Silver Is the New Oil—And the World’s Running Dry
- BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align
- What happened in Cyprus could be coming here
- Elon Musk’s $1 Quadrillion AI IPO
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why